insights_auto
Warum fiel LGND um 2,37%?
Mehr erfahrenchevron_right
LGND:NASDAQ
Ligand Pharmaceuticals
308,79 $
arrow_downward
-2,37%(-7,48) 1 T
308,60 $
arrow_downward
-0,06% (-0,19)bedtimeNachbörse
Geschlossen: 13. Nov., 16:00:01 GMT-5 · USD
search
Alle Symbole
| Symbol | Kurs | Änderung | Änderung in % |
|---|
insights_autoWichtige Einblicke für LGND werden generiert…
Öffnen
313,98 $
Höchstwert
314,79 $
Tiefstwert
308,59 $
Börsenwert
6,18 Mrd.
Durchschn. HVol.
219.421,00
Handelsvolumen
129.021,00
KGV
134,83
52-Wochen-Hoch
326,63 $
52-Wochen-Tief
175,89 $
EPS
2,29 $
Beta
1,07
Aktien im Umlauf
20,00 Mio.
Anzahl der Mitarbeiter
47
Öffnen
313,98 $
Höchstwert
314,79 $
Tiefstwert
308,59 $
Börsenwert
6,18 Mrd.
Durchschn. HVol.
219.421,00
Handelsvolumen
129.021,00
KGV
134,83
52-Wochen-Hoch
326,63 $
52-Wochen-Tief
175,89 $
EPS
2,29 $
Beta
1,07
Aktien im Umlauf
20,00 Mio.
Anzahl der Mitarbeiter
47
Nachrichtenmeldungen
Aus Webquellen und von Nachrichtenpartnern
Investing.com Canada
·
vor 13 Stunden
Form 144 LIGAND PHARMACEUTICALS INCORPORATED For: 13 November By Investing.com
Investing.com Canada
·
vor 14 Stunden
Ligand Pharmaceuticals director Jason Aryeh sells $960,140 in stock By Investing.com
TradingView
·
vor 1 Tag
Ligand Pharmaceuticals Director Sold Shares Worth Over $960K
Profil
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
Über Ligand Pharmaceuticals
CEO-
Mitarbeiter47
GründungsdatumSept. 1987
HauptsitzJupiter, Florida, USA
SektorHealth Care
Branche-
Websiteligand.com